Genmab A/S (GMAB)
52.74
-2.38
(-4.32%)
USD |
NASDAQ |
Nov 05, 16:00
51.90
-0.84
(-1.59%)
After-Hours: 06:17
Genmab SG&A Expense (TTM) : 726.50M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 726.50M |
| March 31, 2026 | 667.61M |
| December 31, 2025 | 627.09M |
| September 30, 2025 | 597.86M |
| June 30, 2025 | 577.90M |
| March 31, 2025 | 561.09M |
| December 31, 2024 | 559.76M |
| September 30, 2024 | 515.82M |
| June 30, 2024 | 513.98M |
| March 31, 2024 | 505.77M |
| December 31, 2023 | 478.47M |
| September 30, 2023 | 470.08M |
| June 30, 2023 | 435.23M |
| March 31, 2023 | 404.97M |
| December 31, 2022 | 375.67M |
| September 30, 2022 | 328.06M |
| June 30, 2022 | 285.89M |
| March 31, 2022 | 238.14M |
| December 31, 2021 | 202.54M |
| September 30, 2021 | 160.86M |
| June 30, 2021 | 135.12M |
| March 31, 2021 | 118.75M |
| December 31, 2020 | 101.83M |
| September 30, 2020 | 82.10M |
| June 30, 2020 | 71.43M |
| Date | Value |
|---|---|
| March 31, 2020 | 56.04M |
| December 31, 2019 | 51.19M |
| September 30, 2019 | 42.84M |
| June 30, 2019 | 39.35M |
| March 31, 2019 | 37.22M |
| December 31, 2018 | 33.77M |
| September 30, 2018 | 31.12M |
| June 30, 2018 | 28.41M |
| March 31, 2018 | 24.74M |
| December 31, 2017 | 22.37M |
| September 30, 2017 | 19.57M |
| June 30, 2017 | 17.75M |
| March 31, 2017 | 16.24M |
| December 31, 2016 | 15.22M |
| September 30, 2016 | 15.06M |
| June 30, 2016 | 14.04M |
| March 31, 2016 | 13.82M |
| December 31, 2015 | 13.57M |
| September 30, 2015 | 14.10M |
| June 30, 2015 | 14.50M |
| March 31, 2015 | 14.47M |
| December 31, 2014 | 14.13M |
| September 30, 2014 | 13.96M |
| June 30, 2014 | 13.09M |
| March 31, 2014 | 12.52M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| AbbVie, Inc. | 15.19B |
| Incyte Corp. | 1.435B |
| Ascendis Pharma A/S | 662.10M |
| Zealand Pharma A/S | 78.53M |
| Novo Nordisk A/S | 7.324B |